Replies to post #117697 on Amarantus Bioscience Holdings Inc (AMBS)

[zoomboom]

they would need to own AMBS shares to hold them.

[JPetroInc]

appear that is precisely right

"the company went from not enough pipeline candidates to too many in actually a very short time period"

but as JN articulated so well, its not the pipe thats the problem, its obtaining the enormous amount of multiple-millions of dollars needed in order to bring them through the requisite development stages

that my friend has so far fallen on the loyal shareholders - because they are unable to obtain financing, an IB, adequate grant funding and/or JV partners, and have relied solely on numerous toxic converts and massive shareprice destroying dilution to fund the operations

for example - where is $5-Mil. coming from to secure the next Lonza milestone:

Acquisition of Cutanogen Corporation

On July 8, 2015, the Company exercised its previously disclosed option to acquire Cutanogen Corporation. Pursuant to a Share Purchase Agreement among the Company and Lonza Walkersville, Inc. (“Lonza”) dated July 14, 2015 (the “Agreement”); the Company paid $4,000,000 to Lonza upon closing. Pursuant to the Agreement, the Company will be required to pay up to $5,000,000 in aggregate milestone payments upon the achievement of certain regulatory milestones.

and this is just one of multiple financial obligations that have set the shareholders in harms way and caused for a collapse in share price, as the overhang needed to pay down the debt load can not be supported by the market buying into the AMBS's business plan

as one analyst said, "AMBS is all over the place"